MS patients in rural areas are 17% less likely to receive DMTs than those in urban areas, a study of Alberta, Canada, ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

This week's Guest Voice features Aranzazu Calzado, who says she was terrified to learn she had MS. Today, she's proud of her ...

Aranzazu Calzado, known to friends as Zazu, has lived in Houston since 1996 after moving from Spain. Diagnosed with primary ...

Columnist Ben Hofmeister knows that living his best life is his mission, so he tries to put his multiple sclerosis in proper context.

Biostate AI and the Accelerated Cure Project will to develop AI models to predict multiple sclerosis progression and ...

The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

MS patients in the U.S. with Medicaid coverage have worse disease outcomes compared with those who have private insurance, a ...

Over five years, relapsing-remitting multiple sclerosis patients in France taking Tysabri have adopted more at-home dosing, a ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Two researchers win the Breakthrough Prize in Life Sciences for their discoveries related to multiple sclerosis disease ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...